• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

Cellectis SA (CLLS)

American Depository Receipt
Sell: $3.15|Buy: $3.99|Change: 0.02 (-0.64%)

Open 

$3.105

Previous close 

$3.12

Trade high 

$3.18

Volume 

75,583

Year high 

$5.4796

Year low 

$2.35

Dividend yield 

–

Market capitalisation 

$312.23 mn

P/E ratio 

–

ISIN 

US15117K1034

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Share price

Performance 11/09/2026

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann

Total return (%)
Cellectis SA- 0.64
More...

Company profile

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Sector 

Healthcare

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2026 AJ Bell. All rights reserved.